VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 25, 2013) -
Preparation and testing of innovative, homogeneous drugs: combining multiple therapies by linking them to a protein which is directly targeted to cancer tumors and has been shown to promote anti-tumor immunity. The Advanced Protein Conjugate Therapeutic (APCT).
Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE:APC) announces that the successful development of pioneering enabling technology designed to link small entities to specific sites on proteins, has allowed APC to begin the process of applying the technology to proteins targeted to cancers. Advanced, targeted therapies are intended to attack primarily cancer cells and are expected to dominate the anti-cancer therapeutics market in the near future.
The Company's technology is based on a proprietary platform that can be used to attach known therapeutic entities to specific sites on proteins; in this case, a protein which not only has shown affinity for specific cancer cells in a broad range of studies, but also has been demonstrated to promote anti-tumor immunity in animal testing. The attachments are designed to enhance the properties of this protein targeted for cancer cells and endow it with additional therapeutic functions. The basis of APC's technology is what the Company regards as the Foundation Trinity: consisting of not only targeted therapy and combination therapy, but homogeneous therapy as well. Homogeneity originates from the utilization of this protein not only as a delivery system, but also as a scaffold upon which to attach each anti-cancer entity to its own specific site on the protein, key to efficient manufacturing and product development. This latter feature differentiates APC from its competitors and affords competitive advantages in homogeneously producing single agents bearing multiple therapies that meet the industrial gold standard of purity.
Over the near term, the Company has made the targeted delivery of anti-cancer drugs to tumor cells its point of focus. This program will involve the following steps and milestones:
- APC plans on synthesizing a number of the aforementioned multicomponent anticancer agents using its patent-pending technology. This effort has begun.
- Contracts will be sought with expert scientists at cutting edge laboratories to perform the testing. This effort has begun.
- Once fully executed agreements are in place, the first round of testing will begin-agents will be screened for their ability to target cancer cells specifically and for any obvious toxic effects on healthy cells.
- In the second round of testing, any promising agents will undergo animal testing to determine the potency and toxicity of the agent against animal models. To the extent possible, a determination of the effectiveness of the APCT in both killing cancer cells with attached chemotherapeutics as well as harnessing the immune system to specifically target tumor cells will be attempted.
The Company anticipates the completion of the above milestones over the next six months.
In summary, APC will seek to forge a new direction that we hope will change the way cancers are treated. The classical concept of a drug as a magic bullet for treating disease, which has underlain R&D since the turn of the 20th century, has evolved to favor simultaneous use of a more diverse and complex arsenal of weapons to meet the challenges of cancer. By analogy, APC expects to implement a strategy that extends the magic bullet concept to a multiple warhead concept in the War on Cancer.
APC specializes in the development and patenting of advanced methods and platform technologies designed to deliver drugs to specific cellular targets. The Company's patent-pending technology creates transportation systems for drugs to target cells that need to be destroyed, such as cancer cells. APC uses its proprietary enabling technology for chemical modification of the carrier proteins. These methods allow the drug, in accord with regulatory requirements, to be site-specifically attached to the carrier protein which tracks to cancers cells. APC is focused on developing the first commercial application of cancer cell targeting by a specific protein family that has a homing instinct for cancer cells. Due to its high affinity for a target receptor on cancer cells, the protein can function as a transport system for drugs linked to its surface, with the prospect of avoiding the debilitating toxic effects that have plagued the use of chemotherapeutic drugs.
By virtue of a similar homing instinct of the protein family for cells in the process of dying, the foregoing technologies are also applicable to the repair of cells where loss of function is a critical event, such as in eye diseases and myocardial infarction.
ON BEHALF OF THE BOARD
Alexander (Allen) Krantz, President and Chief Executive Officer
The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.